Related Experiment Videos
[Cefixime. Microbiologic, kinetic and clinical profile]
Minerva Medica
|October 1, 1991
Summary
Cefixime, a third-generation cephalosporin antibiotic, shows high activity against Gram-negative bacteria and specific Gram-positive strains. Its favorable pharmacokinetics and once-daily dosing make it a valuable option for respiratory tract infections.
Area of Science:
- Microbiology
- Pharmacology
- Clinical Medicine
Context:
- Evaluation of cefixime, an oral third-generation cephalosporin.
- Assessment of its microbiological spectrum, pharmacokinetic properties, and clinical utility.
Purpose:
- To present the comprehensive profile of cefixime.
- To highlight its efficacy and suitability for specific infections.
Summary:
- Cefixime exhibits potent activity against Gram-negative aerobic bacteria and key Gram-positive cocci (e.g., Streptococcus pneumoniae).
- It demonstrates no activity against anaerobic bacteria.
- The antibiotic possesses favorable pharmacokinetic properties, including good tissue distribution, and is indicated for upper and lower respiratory tract infections caused by susceptible pathogens like H. influenzae and B. catarrhalis.
Impact:
- Cefixime expands therapeutic options for bacterial infections.
- Its once-daily dosing regimen enhances patient compliance.
- Provides a new, effective antibiotic for common respiratory infections.